GlassScriptPhysician profile
Pavel Volkov
NPI 1205458452
$1,429.92
in general payments reported to CMS, 2019-2025
24 companies · $500 in 2025
The $500 reported for 2025 was more than what 79% of Physical Medicine & Rehabilitation providers received nationally (typical 2025 total: $138).
See the full distribution for Physical Medicine & Rehabilitation
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $196 · 2022: $79.57 · 2023: $208 · 2024: $446 · 2025: $500.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,154.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,153.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $532.68 | 2023-2025 | Botox |
| Ipsen Biopharmaceuticals, INC | $153.37 | 2023-2025 | Dysport |
| Astrazeneca Pharmaceuticals LP | $103.99 | 2021 | |
| Allergan, INC. | $96.35 | 2021-2022 | |
| Bioventus LLC | $79.88 | 2023-2025 | Durolane, Xcell, Supartz Fx Sodium Hyaluronate |
| Boston Scientific Corporation | $65.34 | 2024 | |
| Medtronic, INC. | $51.05 | 2023-2024 | Activos 10 Bone Cement |
| Trice Medical, INC. | $36.08 | 2025 | |
| Si-Bone, INC. | $27.79 | 2025 | |
| Janssen Pharmaceuticals, INC | $26.27 | 2022 | |
| Pfizer INC. | $24.65 | 2025 | |
| Scilex Pharmaceuticals INC. | $24.13 | 2023 | Ztlido |
| Avanir Pharmaceuticals, INC. | $20.75 | 2022 | |
| Merz Pharmaceuticals, LLC | $20.57 | 2023 | Xeomin |
| Nevro Corp. | $20.03 | 2024 | Senza |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Averitas Pharma INC. | $19.66 | 2024 | Qutenza |
| Solventum Corporation | $17.88 | 2025 | Activ.A.C. |
| Orthofix Medical, INC. | $17.60 | 2025 | Physio-Stim |
| Vertex Pharmaceuticals Incorporated | $16.73 | 2025 | |
| Ibsa Pharma INC. | $16.53 | 2022 | |
| Siemens Medical Solutions USA, INC. | $15.98 | 2025 | Cios Flow |
| Collegium Pharmaceutical, INC. | $15.25 | 2025 | Belbuca |
| Otsuka America Pharmaceutical, INC. | $15.22 | 2023 | Nuedexta |
| Sanofi-Aventis U.S. LLC | $12.14 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pavel Volkov listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.